Translational Drug Development (TD2)
Ryan Ellsworth is a Senior Clinical Programmer at Translational Drug Development (TD2) since May 2018, with extensive experience in clinical programming across multiple organizations. Prior roles include Clinical Programmer III positions at Covance and Theorem Clinical Research, where responsibilities encompassed building databases in RAVE, providing guidance to clinical study teams, and mentoring new employees. Previously, as Clinical Systems Technical Manager at Amgen, Ryan designed and maintained complex studies, trained new designers, and ensured quality in study builds. Earlier experience includes roles at Sites USA, performing statistical analysis, and at i3 Research, designing databases for a wide range of pharmaceutical studies. Ryan holds a Master's degree in Computers and Information Systems from the University of Phoenix and a Bachelor's degree in Business Statistics from Brigham Young University.
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.